Phosphonium Ion Channel Blockers for Selective Nociceptor Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management therapies lack selective inhibitors for nociceptors, cough receptors, and pruriceptors, often causing unwanted effects on non-nociceptive neurons and failing to effectively treat neurogenic inflammation.
Innovation Solution
Development of compounds represented by Formula (I) that selectively inhibit nociceptors and treat pain, itch, and neurogenic inflammation by entering nociceptors through large pore channels like TRPV1, TRPA1, TRPM8, ASIC, and P2X receptors, without affecting non-nociceptive neurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If local anesthetics are used to block nociceptors, then pain transmission is inhibited, but non-nociceptive neurons are also blocked causing general numbness and motor deficits
Solution Approach 1:
The invention applies local quality by designing compounds with specific properties (small size, cationic charge) that enable selective entry into nociceptors through TRPV1 channels. Once inside, the compounds locally block sodium channels only within nociceptors, leaving other neuron types unaffected. This spatial and functional selectivity resolves the contradiction between effective pain relief and avoidance of side effects on non-nociceptive neurons.
Solution Approach 2:
The invention uses TRPV1 channels as an intermediary mechanism to deliver the sodium channel blocker selectively into nociceptors. The TRPV1 channel serves as a gateway that the compound exploits to gain intracellular access specifically in pain-sensing neurons. This intermediary approach allows the compound to achieve its blocking effect selectively without directly targeting or affecting other neuron types, thus resolving the contradiction between efficacy and safety.
2Reliability
If membrane-permeable compounds are used to reach intracellular sodium channels, then channel blocking is achieved, but selectivity for nociceptors is lost
Solution Approach 1:
The invention changes the parameters of the compound to achieve the desired selectivity. Specifically, it uses small molecular size (enabling passage through TRPV1 pores) and cationic charge (facilitating entry through activated TRPV1 channels). These parameter modifications allow the compound to selectively enter nociceptors while maintaining its ability to block intracellular sodium channels, thus resolving the contradiction between achieving channel blocking and maintaining nociceptor selectivity.
3Adaptability or versatility
If charged derivatives of local anesthetics are used to block sodium channels, then selectivity for nociceptors improves, but membrane permeability is lost preventing drug entry
Solution Approach 1:
The invention uses activated TRPV1 channels as an intermediary pathway to overcome the membrane permeability barrier. The charged compound cannot pass through the lipid bilayer directly, but it exploits the TRPV1 channel pore (when activated by noxious stimuli) as a water-filled conduit to reach the intracellular sodium channel binding site. This intermediary mechanism resolves the contradiction between maintaining charge for selectivity and achieving membrane entry.
Solution Approach 2:
The invention extracts the membrane permeability requirement from the compound design by utilizing the TRPV1 channel as an alternative entry route. Instead of requiring the compound to penetrate the lipid membrane directly, the design extracts this function and replaces it with channel-mediated transport. This allows the compound to maintain its charged, selective properties while still achieving intracellular delivery through the TRPV1 gateway.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively alleviate pain, itch, and neurogenic inflammation by selectively targeting nociceptors, reducing unwanted side effects on other neurons and providing targeted pain relief.
Implementation Method 1
small, cationic drug molecules gain access to the intracellular compartment of sensory neurons via entry through large pore receptor/ion channels
Implementation Method 2
These anesthetics block sodium channels and thereby the excitability of all neurons
Data Source
AI summary
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.